From GlobeNewswire: 2025-06-02 16:30:00

Entrada Therapeutics granted 23,820 RSUs to new employees under the Inducement Equity Plan. The RSUs will vest over time, with one-fourth vesting after a year and 6.25% quarterly thereafter. Entrada is focused on developing medicines that target intracellular issues previously deemed inaccessible. Their EEV™-therapeutics aim to improve the delivery of therapeutics for various diseases. The company is working on programs for neuromuscular and ocular diseases, with lead oligonucleotide programs for Duchenne patients. Entrada has also partnered on a clinical-stage program for myotonic dystrophy type 1. For more information, visit their website.



Read more at GlobeNewswire: Entrada Therapeutics Announces Inducement Grants Under